Condition
NK-Cell Lymphoma, Unclassifiable
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Terminated1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT02978625Phase 2Active Not Recruiting
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT03075553Phase 2Terminated
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Showing all 2 trials